Safety and implementation of phase I randomized GLA-SE–adjuvanted CH505TF gp120 HIV vaccine trial in newborns
Journal of Clinical Investigation · 02.06.2025 · 135 (11)
DOI: 10.1172/jci186927 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Investigation, online erschienen am 03.04.2025. Verfasst von Avy Violari und 22 weiteren Autor:innen. Beteiligte Einrichtung: Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Hauptthemen laut MEDLINE: AIDS Vaccines, HIV Envelope Protein gp120, HIV Infections, Adjuvants, Immunologic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
BACKGROUND The neonatal immune system is uniquely poised to generate broadly neutralizing antibodies (bnAbs), and thus infants are ideal for evaluating HIV vaccine candidates. We present the design and safety of a new-in-infants glucopyranosyl lipid A–stable emulsion (GLA-SE) adjuvant admixed with a first-in-infant CH505 transmitter-founder (CH505TF) gp120 immunogen designed to induce precursors for bnAbs against HIV. METHODS HIV Vaccine Trials Network 135 is a phase I randomized, placebo-controlled trial of CH505TF plus GLA-SE or placebo. Healthy infants aged ≤5 days, born to mothers living with HIV but HIV nucleic acid–negative at birth, were randomized to 5 doses of CH505TF plus GLA-SE or placebo at birth and 8, 16, 32, and 54 weeks. RESULTS Thirty-eight infants (median age 4 days; interquartile range 4–4.75 days) were enrolled November 2020 to January 2022. Among 28 infants assigned to receive CH505TF plus GLA-SE and 10 assigned to receive placebo, most completed the 5-dose immunization series (32/38) and follow-up (35/38). Solicited local and systemic reactions were more frequent in vaccine (8, 28.6% local; 16, 57.1% systemic) versus placebo recipients (1, 10% local, P = 0.25; 4, 40.0% systemic, P = 0.38). All events were grade 1 except 2 grade 2 events (pain, lethargy). Serious vaccine-related adverse events were not recorded. CONCLUSION This study illustrates the feasibility of conducting trials of new-in-infants adjuvanted HIV vaccines in HIV-exposed infants receiving standard infant vaccinations. The safety profile of the CH505TF plus GLA-SE vaccine was reassuring. TRIAL REGISTRATION ClinicalTrials.gov NCT04607408. FUNDING National Institute of Allergy and Infectious Diseases of the NIH under grants UM1AI068614, UM1AI068635, and UM1AI068618.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Department of Allergy and Infectious Disease, Division of Medicine, University of Washington, Seattle, Washington, USA.
- Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- Precision Vaccines Program, Boston Children's Hospital, Boston, Massachusetts, USA.
- Harvard Medical School, Department of Neonatology, Beth Israel Medical Center, Boston, Massachusetts, USA.
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Violari, A., Otwombe, K., Hahn, W., Chen, S., Josipovic, D., Baba, V., Angelidou, A., Smolen, K. K., Levy, O., Mkhize, N. N., Woodward Davis, A. S., Martin, T. M., Haynes, B. F., Williams, W. B., Sagawa, Z. K., Kublin, J. G., Polakowski, L., Brewinski Isaacs, M., Yen, C., …, & Gray, G. E. (2025). Safety and implementation of phase I randomized GLA-SE–adjuvanted CH505TF gp120 HIV vaccine trial in newborns. Journal of Clinical Investigation, 135(11). https://doi.org/10.1172/jci186927
Vancouver
Violari A, Otwombe K, Hahn W, Chen S, Josipovic D, Baba V, et al. Safety and implementation of phase I randomized GLA-SE–adjuvanted CH505TF gp120 HIV vaccine trial in newborns. Journal of Clinical Investigation. 2025;135(11). doi:10.1172/jci186927
BibTeX
@article{Violari2025,
author = {Violari, Avy and Otwombe, Kennedy and Hahn, William and Chen, Shiyu and Josipovic, Deirdre and Baba, Vuyelwa and Angelidou, Asimenia and Smolen, Kinga K and Levy, Ofer and Mkhize, Nonhlanhla N and Woodward Davis, Amanda S and Martin, Troy M and Haynes, Barton F and Williams, Wilton B and Sagawa, Zachary K and Kublin, James G and Polakowski, Laura and Brewinski Isaacs, Margaret and Yen, Catherine and Tomaras, Georgia and Corey, Lawrence and Janes, Holly and Gray, Glenda E},
title = {Safety and implementation of phase I randomized GLA-SE–adjuvanted CH505TF gp120 HIV vaccine trial in newborns},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {11},
doi = {10.1172/jci186927}
}
EUVIMED